Differential effects of free and liposome encapsulated amikacin on the survival of Mycobacterium avium complex in mouse peritoneal macrophages

Authors

L. Kesavalu, National Jewish Medical and Research Center
Jayne A. Goldstein, University of California, San Francisco
Robert J. Debs, University of California, San Francisco
Nejat Düzgüneş, University of California, San FranciscoFollow
Pattisapu R.J. Gangadharam, National Jewish Medical and Research Center

ORCiD

Nejat Düzgüneş: 0000-0001-6159-1391

Department

Biomedical Sciences

Document Type

Article

Publication Title

Tubercle

ISSN

0041-3879

Volume

71

Issue

3

DOI

10.1016/0041-3879(90)90079-N

First Page

215

Last Page

217

Publication Date

1-1-1990

Abstract

Liposome-encapsulated amikacin shows significantly greater inhibitory activity against the survival of Mycobacterium avium complex inside mouse peritoneal macrophages than the free drug. Similar results were obtained whether the drug was added simultaneously with, 48 h prior to, or 48 h after the addition of mycobacteria to the macrophages. These observations support the hypothesis that the in vivo intravenous delivery of liposome-encapsulated amikacin results in the localization of the antibiotic in phagosomes containing mycobacteria inside resident macrophages of the liver and spleen. © 1990.

Recommended Citation

Kesavalu, L., Goldstein, J. A., Debs, R. J., Düzgüneş, N., & Gangadharam, P. R. (1990). Differential effects of free and liposome encapsulated amikacin on the survival of Mycobacterium avium complex in mouse peritoneal macrophages. Tubercle, 71(3), 215–217. DOI: 10.1016/0041-3879(90)90079-N
https://scholarlycommons.pacific.edu/dugoni-facarticles/701